Bausch + Lomb Corporation has recently received approval from the U.S. Food and Drug Administration (FDA) for its innovative TENEO Excimer Laser Platform, designed for laser-assisted in situ keratomileusis (LASIK) vision correction surgery, specifically focusing on myopia and myopic astigmatism. Luc Bonnefoy, President of Global Surgical at Bausch + Lomb, highlighted the platform's global success and versatility, emphasizing its precision, speed, and advanced features.

The key features of the TENEO Excimer Laser Platform include exceptional accuracy, with an advanced eye-tracker operating at 1,740Hz, ensuring minimal impact from patient eye movements and optimizing post-operative outcomes. The high-speed laser, operating at 500Hz, stands out as the fastest among excimer lasers in the United States.

In terms of efficiency, the platform boasts a customizable graphical user interface touchscreen, simplifying setup and providing convenient access to patient data. The TENEO software streamlines surgical planning by treating manifest refraction without the need for a nomogram, reducing pre-treatment steps to a straightforward three-step process: select patient, confirm treatment, and treat. Furthermore, the compact design (0.6m2) addresses concerns about limited clinical space, making it the smallest excimer laser unit in the United States.

Regarding usability, the platform has been meticulously engineered for the comfort of both surgeons and patients. It features a 360° swiveling microscope that adapts to surgeon height and posture, ensuring optimal comfort during procedures. The treatment bed accommodates patients of all sizes, swings out for easy access, and can be customized for optimal head positioning. The bed's swiveling capability for a second treatment device enhances patient comfort and simplifies the overall surgical process.

The FDA's approval of the TENEO Excimer Laser Platform is considered a significant milestone in advancing laser vision correction technology in the United States, offering a promising solution for myopia and myopic astigmatism.

Source: businesswire.com

Report Abuse